Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Foundation Medicine and Memorial Sloan-Kettering Cancer Center Announce Partnership

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Partners will co-develop a genomic test to help guide treatment decisions for patients diagnosed with leukemia, lymphoma or myeloma.

Foundation Medicine and Memorial Sloan-Kettering Cancer Center have announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.

This effort will focus on co-development of a new Foundation Medicine molecular diagnostic product designed to match patients with hematologic cancers (leukemia, lymphoma or myeloma) with the most rational targeted therapies or clinical trials for their cancer.

Leaders in hematology from Memorial Sloan-Kettering will help accelerate product development by providing clinical and genomic expertise.

This product complements FoundationOne™, Foundation Medicine’s first product, which offers a similar fully informative genomic profile for solid tumors and likewise provides a concise report to assist physicians in matching patients with the targeted drugs or clinical trials best suited for their unique cancer. FoundationOne was launched in 2012.

“The development of clinical grade sequencing is rapidly changing the practice of oncology, enabling us to more precisely understand and target the genomic alterations that drive a patient’s individual cancer,” said Craig B. Thompson, M.D., president and chief executive officer of Memorial Sloan-Kettering Cancer Center.

Thompson continued, “We are partnering with Foundation Medicine to develop a best-in-class assay for hematologic cancers because we view achieving this goal as an extension of our mission as a comprehensive cancer center: making it possible for all patients to be treated with the therapy that is matched with their individual cancer.”

“Memorial Sloan-Kettering is one of the world’s premier cancer centers with deep scientific and clinical understanding of hematologic cancers and a commitment to driving a new genomic paradigm of individualized cancer care,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine.

Pellini continued, “Our approach is to collaborate with leaders like Memorial Sloan-Kettering across all areas of clinical oncology and cancer genomics and seek partners who are equally committed to the changing paradigm of cancer care. This is the ideal partnership to support the development of our new product for patients with hematologic malignancies.”

This new test is being developed using RNA sequencing in addition to DNA sequencing to better enable identification of the unique genes and classes of genomic alterations that are characteristic of hematologic malignancies.

Similar to FoundationOne, the new hematologic malignancy test will assist physicians by matching these alterations with targeted treatment options that may be relevant to the patient’s genomic profile based on a comprehensive review of published literature.

The test will be based on technology, methods and computational algorithms developed by Foundation Medicine, and Foundation Medicine will commercialize the test both in the United States and internationally.

Memorial Sloan-Kettering will help accelerate the development and optimization of the product by contributing their clinical and genomic expertise in hematologic malignancies.

Foundation Medicine operates a CLIA-certified lab in Cambridge, Mass. and receives clinical patient samples from academic medical centers and community hospitals all over the world. The new test is expected to be commercially available by year-end 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Foundation Medicine Extends and Expands Collaboration with Novartis
Collaboration will now extend through at least September 2016.
Wednesday, January 08, 2014
Foundation Medicine and AstraZeneca Announce Genomic Profiling Collaboration
Collaboration seeks to enhance clinical trial design by identifying genomic predictors of response to targeted cancer therapies.
Monday, November 12, 2012
Foundation Medicine Enters Extensive Collaboration with Novartis
Pilot agreement extended to a broad financial commitment over three years.
Monday, June 11, 2012
Foundation Medicine’s Next-Generation Sequencing Data to be Presented at 103rd AACR Annual Meeting 2012
Genomic profile demonstrates high concordance with existing commercial assays and identifies broader range of actionable alterations.
Wednesday, March 28, 2012
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer
Findings highlight clinical application of next-generation sequencing to suggest targeted therapeutic options for patients.
Tuesday, February 14, 2012
Foundation Medicine Announces Collaboration with Sanofi
Fifth partnership will help translate cancer genomic science to clinical results. Foundation Medicine will use their genomic sequencing and analytic capabilities to identify genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates.
Friday, January 13, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!